What it sells
RNAx platform: an mRNA-encoded protein that dampens innate immune response to make RNA vaccines more tolerable.
Business model breakdown
Workflow: what inputs become what output?
Co-express RNAx with vaccine RNA so cells dampen overactive innate response to RNA and LNPs.
Economics: what it saves and how it charges
UnverifiedTherapeutics/platform licensing or partnership revenue.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2019 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.